Marginal zone lymphoma: biology and molecular genetics

ESH eLearning, Ming Qing Du, 210035

Marginal zone lymphoma. Prognostic models.

ESH eLearning, Carlos Montalban, 210036

Clinical aspects

ESH eLearning, Catherine Thieblemont, 210037

Treatment of splenic marginal zone lymphoma

ESH eLearning, Barbara Kiesewetter, 210038

Treatment of nodal marginal zone lymphoma

ESH eLearning, Catherine Thieblemont, 210039

Treatment of MALT lymphoma

ESH eLearning, Emanuele Zucca, 210040

Novel targeted therapies in CL - Ibrutinib

ESH eLearning, John Gribben, 210025

Idelalisib

ESH eLearning, Michael J. Keating, 210026

Venetoclax

ESH eLearning, Peter Hillmen, 210027

Follicular lymphoma; from genetics to pathogenesis

ESH eLearning, Riccardo Dalla-Favera, 210028

Clonal evolution of follicular lymphoma

ESH eLearning, Michael R. Green, 210029

Integrating molecular diagnostics for improved patient stratification in follicular lymphoma

ESH eLearning, Oliver Weigert, 210030

Advanced stage patient, first line

ESH eLearning, Christian Buske, 210031

Treatment of follicular lymphoma (FL): Salvage therapy

ESH eLearning, Vincent Ribrag, 210032

New agents

ESH eLearning, Gilles Salles, 210033

Micro RNA dysregulation to identify targets for therapy in hematopoietic malignancies

ESH eLearning, Carlo M. Croce, 210019

Genetic portrait of CLL

ESH eLearning, Cathy Wu, 210020

Predictive biomarkers in CLL

ESH eLearning, Davide Rossi, 210021

FCR

ESH eLearning, Michael J. Keating, 210022

BR

ESH eLearning, Olivier Tournilhac, 210023

Chlorambucil plus anti-CD20 MoAb

ESH eLearning, Valentin Goede, 210024

Myeloma Hub

ESH eLearning, ESH , 204612

iCMLf Prize talk

ESH eLearning, Jerry Radich, 205141

John Goldman Prize Talk

ESH eLearning, Tim Hughes, 205140

Janet Rowley Prize talk

ESH eLearning, Mhairi Copland, 205142

Targeting non-coding RNAs in leukemia

ESH eLearning, Ramiro Garzon, 204647

Exportin (XPO1) inhibitors for the treatment of AML

ESH eLearning, Ramiro Garzon, 204648

Novel targets for AML

ESH eLearning, Ramiro Garzon, 204649

The spliceosome mutations that can cause hematological malignancies

ESH eLearning, Omar Abdel-Wahab, 204650

Efficacy of first generation FLT3 inhibitors for AML

ESH eLearning, Miguel Sanz, 204651

The need for collaboration amongst hospitals: learning from RATIFY

ESH eLearning, Miguel Sanz, 204652

Why are new molecules typically combined with standard chemotherapy?

ESH eLearning, Miguel Sanz, 204653

Integrating midostaurin into FLT3 positive AML treatment

ESH eLearning, Miguel Sanz, 204654

Role of genetics in hematological malignancies: expanding our understanding

ESH eLearning, Jane Churpek, 204655

Combinations with FLT3 inhibitors: the way forward for AML treatment

ESH eLearning, Katherine Smith, 204656

Resistance mechanisms to FLT3 inhibitors in AML

ESH eLearning, Katherine Smith, 204657

Infrastructure for AML treatment in Spain

ESH eLearning, Jorge Sierra, 204658

Finding novel treatment options for relapsed/progressing AML

ESH eLearning, Jorge Sierra, 204659

The importance of collaboration in AML research

ESH eLearning, Omar Abdel-Wahab, 204660

Neomorphic mutations driving hematological cancers

ESH eLearning, Omar Abdel-Wahab, 204661

Therapeutics targeting splicing in hematological malignancies

ESH eLearning, Omar Abdel-Wahab, 204662

What are the drivers of leukemia?

ESH eLearning, Omar Abdel-Wahab, 204663

The benefits of patient advocacy groups

ESH eLearning, Jane Churpek, 204664

Developing an understanding of disease progression in MDS and AML

ESH eLearning, Jane Churpek, 204665

Balancing hereditary research with patient care in leukemia

ESH eLearning, Jane Churpek, 204666

Combination therapies and improving overall survival in AML

ESH eLearning, Mark Levis, 204667

The challenges of using kinase inhibitors for AML treatment

ESH eLearning, Mark Levis, 204668

Venetoclax for elderly AML patients

ESH eLearning, Mark Levis, 204669

The drugs being used to treat newly diagnosed AML patients

ESH eLearning, Mark Levis, 204670

AML immunotherapy: patients need to be well informed

ESH eLearning, Marion Subklewe, 204671

The rapid progression of IDH1/2 mutant enzyme inhibitors through clinical trials

ESH eLearning, Stéphane , 204672

Advising AML patients to participate in clinical trials

ESH eLearning, Marina Konopleva, 204673

One size does not fit all: AML subtype treatment approaches

ESH eLearning, Mark Levis, 204674

AML immunotherapy: pre-clinical data to look forward to at ASH 2017

ESH eLearning, Marion Subklewe, 204675

AML clinical trials: early stage vs. relapse/refractory patients

ESH eLearning, Marion Subklewe, 204676

T-cell engaging antibodies: what lessons have we learnt?

ESH eLearning, Marion Subklewe, 204677

Upcoming clinical trials for venetoclax chemotherapy combinations for AML

ESH eLearning, Marina Konopleva, 204678

Providing the relevant information to patients: a changing approach in Spain

ESH eLearning, Jorge Sierra, 204679

What are the alternative treatment options for relapsed or elderly AML patients?

ESH eLearning, Jorge Sierra, 204680

Cytokine release syndrome: a limiting factor for AML treatment

ESH eLearning, John DiPersio, 204681

Bispecific agents: the future of AML and MDS treatment?

ESH eLearning, John DiPersio, 204682

The problem of treating AML with CD123-targeting drugs

ESH eLearning, John DiPersio, 204683

Mimetics: the future of AML treatment?

ESH eLearning, Andrew Wei, 204684

Highly targeted medication for AML

ESH eLearning, Andrew Wei, 204685

Combating AML

ESH eLearning, Andrew Wei, 204686

Current research into pro-apoptosis medication for leukemia

ESH eLearning, Andrew Wei, 204687

The molecular mechanisms of epigenetic therapies: LTRs and TINATs

ESH eLearning, Christoph Plass, 204688

The potential benefits of epigenetic therapy research

ESH eLearning, Christoph Plass, 204689

GATA2 and its influence on AML

ESH eLearning, Emery Bresnick, 204690

Collaboration and cooperation in hematology-oncology research

ESH eLearning, Emery Bresnick, 204691

The use of second generation FLT3 inhibitors for AML

ESH eLearning, Francesco Lo-Coco, 204692

The standardization of molecular diagnostics for myeloid diseases in Italy

ESH eLearning, Francesco Lo-Coco, 204693

New treatments for AML using inhibitors

ESH eLearning, Francesco Lo-Coco, 204694

The future of leukemia treatment in the elderly

ESH eLearning, John DiPersio, 204695

When to use bispecifics for AML

ESH eLearning, John DiPersio, 204696

Expanding trials using bispecifics

ESH eLearning, John DiPersio, 204697

The challenges facing elderly AML treatment

ESH eLearning, Lars Bullinger, 204698

Adapting AML treatment for elderly patients

ESH eLearning, Lars Bullinger, 204699

Translational research in Berlin to improve AML treatment outcomes

ESH eLearning, Lars Bullinger, 204700

Reassuring patients with AML

ESH eLearning, Lars Bullinger, 204701

Selecting AML patients for intensive treatment

ESH eLearning, Marina Konopleva, 204702

Promising results for venetoclax combination therapies in elderly AML

ESH eLearning, Marina Konopleva, 204703

An overview of immunotherapies for leukemia

ESH eLearning, Ravindra Majeti, 204704

Tackling CD47-positive malignancies

ESH eLearning, Ravindra Majeti, 204705

Pre-leukemic stem cells: a telltale sign of AML

ESH eLearning, Ravindra Majeti, 204706

Game-changing treatments for leukemia

ESH eLearning, Ravindra Majeti, 204707

CAR T-cells and CRISPR: The future of AML treatment

ESH eLearning, Saar Gill, 204708

The development of novel treatment modalities: regulations and expectations

ESH eLearning, Saar Gill, 204709

Transferring lessons learnt from treating ALL to AML

ESH eLearning, Saar Gill, 204710

Price vs. performance: CAR T-cells

ESH eLearning, Saar Gill, 204711

The potential of differentiation therapies for AML

ESH eLearning, Stéphane de Botton, 204712

The next steps for the IDH2 inhibitor drug enasidenib

ESH eLearning, Stéphane de Botton, 204713

Working with smaller research companies

ESH eLearning, Stéphane de Botton, 204714

The future of AML and MDS diagnosis and treatment

ESH eLearning, Stéphane de Botton, 204715

New generation studies in follicular and mantle cell lymphoma in the US National Clinical Trials Network (NCTN)

ESH eLearning, Little Richard, 202162

European Mantle Cell Network

ESH eLearning, Martin Dreyling, 202163

Activities of the NCRI and UK lymphoma studies

ESH eLearning, Collins Graham, 202164

MRD in CLL

ESH eLearning, Andy Rawstron, 202155

Initial diagnostic work up of MCL

ESH eLearning, Martin Dreyling, 202156

Status of allogeneic transplant immunotherapy compared to CAR T cells (a comparative analysis)

ESH eLearning, Maloney David, 202157